


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which

R¹ is hydrogen, halogen, CN, nitro, SO₂R⁴, OH, OR⁴, S(O)xR⁴, SO₂NR⁵R⁶, CONR⁵R⁶, NR⁵R⁶, aryl (optionally substituted by chlorine or fluorine), C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₁-₆ alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen, OR⁸ and NR⁵R⁶, S(O)_xR⁷ where x is 0, 1 or 2;

R² is hydrogen, halogen, CN, SO₂R⁴ or CONR⁵R⁶, CH₂OH, CH₂OR⁴ or C₁-alkyl, the latter group being optionally substituted by one or more substituents independently selected from halogen atoms, OR⁸ and NR⁵R⁶, S(O)_xR⁷ where x is 0, 1 or 2;

R³ is aryl or heteroaryl each of which is optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, nitro, OH, SO₂R⁴, OR⁴, SR⁴, SOR⁴, SO₂NR⁵R⁶, CONR⁵R⁶, NR⁵R⁶, NHCOR⁴, NHSO₂R⁴, NHCO₂R⁴, NR⁷SO₂R⁴, NR⁷CO₂R⁴, C₂-C₆

alkenyl, C₂-C₆ alkynyl, C₁₋₆ alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen atoms, OR⁸ and NR⁵R⁶, S(O)_xR⁷ where x = 0,1 or 2;

R⁴ represents aryl, heteroaryl, or C₁₋₆alkyl all of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, heteroaryl, OR¹⁰, OH, NR¹¹R¹², S(O)_xR¹³ (where x = 0,1 or 2), CONR¹⁴R¹⁵, NR¹⁴COR¹⁵, SO₂NR¹⁴R¹⁵, NR¹⁴SO₂R¹⁵, CN, nitro;

R⁵ and R⁶ independently represent a hydrogen atom, a C₁₋₆alkyl group, or an aryl,or a heteroaryl, the latter three of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, OR⁸ and NR¹⁴R¹⁵, CONR¹⁴R¹⁵, NR¹⁴COR¹⁵, SO₂NR¹⁴R¹⁵, NR¹⁴SO₂R¹⁵; CN, nitro

or

R⁵ and R⁶ together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)_x where x = 0,1 or 2, NR¹⁶, and itself optionally substituted by C₁₋₃ alkyl;

R⁷ and R¹³ independently represent a C_{1-C₆}, alkyl, an aryl or a heteroaryl group, all of which may be optionally substituted by halogen atoms;

R⁸ represents a hydrogen atom, C(O)R⁹, C_{1-C₆} alkyl (optionally substituted by halogen atoms or aryl) an aryl or a heteroaryl group (optionally substituted by halogen);

each of R⁹ R¹⁰, R¹¹, R¹², R¹⁴, R¹⁵, independently represents a hydrogen atom, C_{1-C₆} alkyl, an aryl or a heteroaryl group; and

R¹⁶ is hydrogen, C₁₋₄ alkyl, -COC_{1-C₄} alkyl, COYC_{1-C₄}alkyl where Y is O or NR⁷.

each of R⁹ R¹⁰, R¹¹, R¹², R¹⁴, R¹⁵, independently represents a hydrogen atom, C_{1-C₆} alkyl, an aryl or a heteroaryl group (all of which may be optionally substituted by halogen atoms); and

R¹⁶ is hydrogen, C₁₋₄ alkyl, -COC_{1-C₄} alkyl, COYC_{1-C₄}alkyl where Y is O or NR⁷.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear, branched or cyclic;

wherein the compound of formula (I) is not (2-methyl-3-(2-nitrophenylthio)-1-indolyl)acetic acid.

2. (Original) A compound according to claim 1 in which R¹ is aryl, hydrogen, methyl, chloro, fluoro, nitrile, nitro, bromo, iodo, SO₂Me, SO₂Et, NR⁴R⁵, SO₂N-alkyl₂.

3. (Previously presented) A compound according to claim 1 in which R² is C₁₋₆alkyl.

4. (Original) A compound according to claim 3 in which R³ is quinolyl, phenyl or thiazole. substituted by one or more fluorine, chlorine, methyl, ethyl, isopropyl, methoxy, SO₂Me, trifluoromethyl or aryl groups.

5. (Original) A compound according to claim 1 selected from:

3-[(4-chlorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(2-chloro-4-fluorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(3-chloro-4-fluorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(2-methoxyphenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(3-fluorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(4-ethylphenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(2-chlorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(2,5-dichlorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(4-fluorophenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(4-chloro-2-methylphenyl)thio]-2,5-dimethyl-1H-indol-1-acetic acid;
3-[(4-chlorophenyl)thio]-4-cyano-2,5-dimethyl-1H-indole-1-acetic acid;
5-chloro-3-[(4-chlorophenyl)thio]-6-cyano-2-methyl-1H-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-4-(ethylsulfonyl)-7-methoxy-2-methyl-1H-indole-1-acetic acid;


3-[(4-chlorophenyl)thio]-4-[(diethylamino)sulfonyl]-7-methoxy-2-methyl-1*H*-indole-1-acetic acid;
4-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
5-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
6-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
7-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-2-methyl-5-(methylsulfonyl)-1*H*-indole-1-acetic acid;
2-methyl-3-[(4-methylphenyl)thio]-6-(methylsulfonyl)-1*H*-indole-1-acetic acid;
4-bromo-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-4-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-2-methyl-4-(1-piperazinyl)-1*H*-indole-1-acetic acid;
5-bromo-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-2-methyl-5-phenyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-5-cyano-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-cyanophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid,
3-[(3-methoxyphenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid;
3-[(4-methoxyphenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid,
3-[(3-ethylphenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid
2,5-dimethyl-3-[(2-methylphenyl)thio]-1*H*-indole-1-acetic acid;
3-[(3-chlorophenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid,
3-[(2-Fluorophenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid,
3-[(2,6-Dichlorophenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid;
3-(1*H*-Imidazol-2-ylthio)-2,5-dimethyl-1*H*-indole-1-acetic acid,
2,5-Dimethyl-3-(1*H*-1,2,4-triazol-3-ylthio)-1*H*-indole-1-acetic acid;
2,5-Dimethyl-3-[(4-methyl-4*H*-1,2,4-triazol-3-yl)thio]-1*H*-indole-1-acetic acid;
2,5-Dimethyl-3-[(4-methyl-2-oxazolyl)thio]-1*H*-indole-1-acetic acid;
2,5-Dimethyl-3-[(1-methyl-1*H*-imidazol-2-yl)thio]-1*H*-indole-1-acetic acid;
2,5-Dimethyl-3-[[4-(methylsulfonyl)phenyl]thio]-1*H*-indole-1-acetic acid,
2,5-Dimethyl-3-(8-quinolinylthio)-1*H*-indole-1-acetic acid,
3-[(4-Chlorophenyl)thio]-5-fluoro-2,4-dimethyl-1*H*-indole-1-acetic acid;
3-[(4-Cyanophenyl)thio]-5-fluoro-2,4-dimethyl-1*H*-indole-1-acetic acid;

3-[(2-Chlorophenyl)thio]-5-fluoro-2,4-dimethyl-1*H*-indole-1-acetic acid;
5-Fluoro-3-[(2-methoxyphenyl)thio]-2,4-dimethyl-1*H*-indole-1-acetic acid;
5-Fluoro-3-[(2-ethylphenyl)thio]-2,4-dimethyl-1*H*-indole-1-acetic acid;
5-Fluoro-2,4-dimethyl-3-[[2-(1-methylethyl)phenyl]thio]-1*H*-indole-1-acetic acid;
5-fluoro-2,4-dimethyl-3-[[2-(trifluoromethyl)phenyl]thio]-1*H*-indole-1-acetic acid;
2,5-dimethyl-4-(methylsulfonyl)-3-[(4-phenyl-2-thiazolyl)thio]-1*H*-indole-1-acetic acid;
3-[(3-chlorophenyl)thio]-2,5-dimethyl-4-(methylsulfonyl)- 1*H*-indole-1-acetic acid;
3-[(2-chlorophenyl)thio]-2,5-dimethyl-4-(methylsulfonyl)- 1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-5-(methoxycarbonyl)-2-methyl-1*H*-indole-1-acetic acid;
5-carboxy-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-2-methyl-4-nitro-1*H*-indole-1-acetic acid;
4-amino-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-4-(ethylamino)-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-4-ido-2-methyl-1*H*-indole-1-acetic acid;
3-[(4-chlorophenyl)thio]-2-methyl-4-phenyl-1*H*-indole-1-acetic acid;
and pharmaceutically acceptable salts thereof.


6-7. (Cancelled)

8. (Original) A method of treating according to claim 7 wherein the disease is asthma or rhinitis.

9. (Original) A process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):



in which R¹, R² and R³ are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (A):



where R¹⁷ is an ester forming group and L is a leaving group in the presence of a base, and optionally thereafter in any order:

- removing any protecting group
- hydrolysing the ester group R¹⁷ to the corresponding acid forming a pharmaceutically acceptable salt.